ArticleFrontiers in neurology2026
Exploring sex hormones as potential prognostic biomarkers in prolonged disorders of consciousness: a sex-specific retrospective study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with prolonged disorders of consciousness (pDoC) present significant clinical challenges, directly influencing awakening strategies and the allocation of healthcare resources. This study aimed to evaluate serum sex hormone levels in pDoC patients and assess their potential for predicting clinical outcomes. Methods: This retrospective study initially screened 142 patients with prolonged disorders of consciousness (pDoC) admitted between January 2023 and January 2025. After applying exclusion criteria, a final cohort of 119 patients (77 males and 42 females) was included for analysis. Within 1 week of enrollment, the Chinese Coma Recovery Scale-Revised (CRS-R) score and serum sex hormone levels were assessed. Outcomes were evaluated at 6 months using the Glasgow Outcome Scale-Extended (GOS-E) and classified as good outcome(GOSE score≥4) or poor outcome(GOSE score <4). Statistical analyses were performed to explore the association between serum sex hormone levels and GOSE scores to identify potential prognostic markers. Results: Among male patients, the good outcome group showed higher testosterone levels ( Conclusion: Serum testosterone showed exploratory, hypothesis-generating associations with favorable outcomes in male pDoC patients. However, these findings did not survive correction for multiple testing, and the predictive performance was modest. Sex hormone levels did not demonstrate clear prognostic value in female patients. These preliminary observations underscore the need for larger, prospective studies with standardized endocrine protocols to validate the potential role of sex hormones as prognostic biomarkers in pDoC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.